DFUs with infection classified as Wagner II and adequate blood perfusion were eligible. Systemic antibiotics and debridement were given to the patients and the proprietary topical cream was applied twice daily by patients at home until healing or for up to 7 weeks. The wound closure and time to wound closure were observed.
3 patients with Wagner Grade II DFUs had a baseline HbA1c 8.2% and mild infection. The proprietary topical cream was used when all of them were having oral antibiotics for infection control. After using the proprietary topical cream for up to 7 weeks, the wound closure occurred on all 3 patients.
This is the first time using the proprietary topical cream in US DFU patients with mild infection and it is worth noting that the wound closure occurrence is much earlier than the reported in the literature. The research of this proprietary formulation was noted that it provides the optimal micro-environment for tissue repair. This study result demonstrates a novel treatment option to accelerate healing for infected DFU.
60% of diabetic foot ulcer (DFUs) were reported to have infection and the treatment strategies with infected DFUs are mostly surgery and antibiotics with standard moisturizing dressing and literature has reported the incidence of wound closure at only 27.5% in 6 months and 44.5% in 12 months.
Given infection remains the leading cause of amputation, overcoming the challenges in healing infected DFUs is urgently needed. This study evaluates the efficacy of a novel topical cream with a proprietary formulation used concurrently with systemic antibiotics in treating infected DFUs.